Bispecific T cell engagers (BiTEs) were one of the first antibody-based leukemia therapies engineered, with the anti-CD3 × CD19 antibody blinatumomab being the first agent in this class to have garnered FDA approval for the treatment of acute lymphoblastic leukemia (ALL) [11,12]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.